NASDAQ:CLLS Cellectis - CLLS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cellectis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. $3.10 -0.04 (-1.27%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$3.03▼$3.1450-Day Range$1.85▼$3.8452-Week Range$1.83▼$6.74Volume97,362 shsAverage Volume141,953 shsMarket Capitalization$141.30 millionP/E RatioN/ADividend YieldN/APrice Target$12.20 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Cellectis MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside216.1% Upside$9.80 Price TargetShort InterestHealthy0.61% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.14Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.67) to ($1.08) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.95 out of 5 starsMedical Sector658th out of 1,055 stocksBiological Products, Except Diagnostic Industry104th out of 170 stocks 3.2 Analyst's Opinion Consensus RatingCellectis has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.80, Cellectis has a forecasted upside of 216.1% from its current price of $3.10.Amount of Analyst CoverageCellectis has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.61% of the float of Cellectis has been sold short.Short Interest Ratio / Days to CoverCellectis has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cellectis has recently increased by 31.01%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCellectis does not currently pay a dividend.Dividend GrowthCellectis does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLLS. Previous Next 1.7 News and Social Media Coverage News SentimentCellectis has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cellectis this week, compared to 2 articles on an average week.Search Interest5 people have searched for CLLS on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Cellectis to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cellectis insiders have not sold or bought any company stock.Percentage Held by Insiders16.41% of the stock of Cellectis is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 22.61% of the stock of Cellectis is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Cellectis are expected to grow in the coming year, from ($2.67) to ($1.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cellectis is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cellectis is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCellectis has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cellectis (NASDAQ:CLLS) StockCellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Read More Receive CLLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cellectis and its competitors with MarketBeat's FREE daily newsletter. Email Address CLLS Stock News HeadlinesJanuary 20, 2023 | finance.yahoo.comCellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia TherapeuticsJanuary 20, 2023 | americanbankingnews.comCellectis (NASDAQ:CLLS) Price Target Cut to $6.00 by Analysts at JMP SecuritiesJanuary 28, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 17, 2023 | finance.yahoo.comCalyxt and Cibus Announce the Signing of a Definitive Merger AgreementDecember 29, 2022 | finance.yahoo.comMayflower Bioventures Launches its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial DiseasesDecember 22, 2022 | finance.yahoo.comCellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALLDecember 1, 2022 | finance.yahoo.comCellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022November 10, 2022 | finance.yahoo.comCellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022January 28, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.November 10, 2022 | finance.yahoo.comCellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE)November 4, 2022 | finance.yahoo.comCellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCARTCS1 at ASH 2022October 14, 2022 | businesswire.comWorldwide Repeat Expansion Disorders Treatment Industry to 2030 - North America Remains as the Global Leader and APAC to Present the Largest Opportunity - ResearchAndMarkets.com - Business WireOctober 12, 2022 | finance.yahoo.comCellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022 - Yahoo FinanceOctober 11, 2022 | globenewswire.comCellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022 - GlobeNewswireOctober 11, 2022 | finance.yahoo.comCellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022October 11, 2022 | nasdaq.comIovance (IOVA) Doses First Patient in TIL Cancer Therapy Study - NasdaqOctober 10, 2022 | globenewswire.comIovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy - GlobeNewswireOctober 10, 2022 | finance.yahoo.comIovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy - Yahoo FinanceOctober 5, 2022 | globenewswire.comCellectis to Present Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Supporting Improved Solid Tumor Targeting at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting - GlobeNewswireOctober 5, 2022 | finance.yahoo.comCellectis to Present Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Supporting Improved Solid Tumor Targeting at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual MeetingOctober 5, 2022 | nasdaq.comIovance (IOVA) Focuses on Seeking Nod for Melanoma Therapy - NasdaqOctober 4, 2022 | streetinsider.comForm 424B5 Calyxt, Inc. - StreetInsider.comSeptember 28, 2022 | globenewswire.comCellectis Appoints Mark Frattini, M.D., Ph.D. as Chief - GlobeNewswireSeptember 28, 2022 | finance.yahoo.comCellectis Appoints Mark Frattini, M.D., Ph.D. as Chief Medical OfficerSeptember 23, 2022 | uk.investing.comWhy T2 Biosystems Is Trading Higher By 18%; Here Are 28 Stocks Moving Premarket By Benzinga - Investing.com UKSeptember 23, 2022 | streetinsider.comForm 6-K Cellectis S.A. For: Sep 22 - StreetInsider.comSeptember 21, 2022 | businesswire.comWorldwide CAR T-Cell Therapy Industry to 2028 - Featuring Bluebird Bio, Intellia Therapeutics and Novartis International Among Others - ResearchAndMarkets.com - Business WireSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CLLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cellectis and its competitors with MarketBeat's FREE daily newsletter. Email Address CLLS Company Calendar Last Earnings11/03/2022Today1/28/2023Next Earnings (Estimated)3/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CLLS CUSIPN/A CIK1627281 Webwww.cellectis.com Phone(318) 169-1600Fax33-1-81-69-16-06Employees294Year FoundedN/APrice Target and Rating Average Stock Price Forecast$9.80 High Stock Price Forecast$24.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+293.5%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-114,200,000.00 Net Margins-470.32% Pretax Margin-511.95% Return on Equity-54.50% Return on Assets-31.38% Debt Debt-to-Equity Ratio0.10 Current Ratio2.65 Quick Ratio2.65 Sales & Book Value Annual Sales$67.07 million Price / Sales2.11 Cash FlowN/A Price / Cash FlowN/A Book Value$5.20 per share Price / Book0.60Miscellaneous Outstanding Shares45,580,000Free Float38,099,000Market Cap$141.30 million OptionableOptionable Beta1.95 Key ExecutivesDr. Andre Choulika Ph.D. (Age 58)Co-Founder, CEO & Director Comp: $879.06kDr. David J. D. Sourdive Ph.D. (Age 56)Director, Deputy CEO, Exec. VP of CMC and Manufacturing Comp: $580.28kDr. Bing C. Wang M.B.A. (Age 46)Ph.D., Chief Financial Officer Valerie CrosPrincipal Financial Officer & Principal Accounting OfficerMr. Jean Charles EpinatChief Technological OfficerDr. Philippe Duchateau Ph.D. (Age 60)Chief Scientific Officer Mr. Stephan Reynier M.Sc. (Age 54)MSc, Chief Regulatory & Pharmaceutical Compliance Officer Ms. Marie-Bleuenn Terrier (Age 41)Gen. Counsel & Sec. of the Board of Directors Pascalyne WilsonDirector of CommunicationsMs. Kyung Nam-Wortman (Age 53)Exec. VP & Chief HR Officer More ExecutivesKey CompetitorsINmune BioNASDAQ:INMBVaxartNASDAQ:VXRTAthira PharmaNASDAQ:ATHABioAtlaNASDAQ:BCABIkena OncologyNASDAQ:IKNAView All CompetitorsInsiders & InstitutionsBaillie Gifford & Co.Sold 188,941 shares on 1/24/2023Ownership: 1.316%Jane Street Group LLCSold 146,336 shares on 11/16/2022Ownership: 0.755%Baird Financial Group Inc.Bought 32,640 shares on 11/16/2022Ownership: 0.072%Balyasny Asset Management LLCBought 18,352 shares on 11/16/2022Ownership: 0.040%Marshall Wace LLPSold 5,697 shares on 11/15/2022Ownership: 0.239%View All Institutional Transactions CLLS Stock - Frequently Asked Questions Should I buy or sell Cellectis stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last twelve months. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CLLS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLLS, but not buy additional shares or sell existing shares. View CLLS analyst ratings or view top-rated stocks. What is Cellectis' stock price forecast for 2023? 3 brokers have issued 1-year price objectives for Cellectis' stock. Their CLLS share price forecasts range from $2.00 to $24.00. On average, they anticipate the company's share price to reach $9.80 in the next twelve months. This suggests a possible upside of 216.1% from the stock's current price. View analysts price targets for CLLS or view top-rated stocks among Wall Street analysts. How have CLLS shares performed in 2023? Cellectis' stock was trading at $2.10 on January 1st, 2023. Since then, CLLS shares have increased by 47.6% and is now trading at $3.10. View the best growth stocks for 2023 here. Are investors shorting Cellectis? Cellectis saw a increase in short interest in January. As of January 15th, there was short interest totaling 277,600 shares, an increase of 31.0% from the December 31st total of 211,900 shares. Based on an average daily volume of 117,100 shares, the short-interest ratio is presently 2.4 days. Currently, 0.6% of the shares of the stock are sold short. View Cellectis' Short Interest. When is Cellectis' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023. View our CLLS earnings forecast. How were Cellectis' earnings last quarter? Cellectis S.A. (NASDAQ:CLLS) issued its quarterly earnings data on Thursday, November, 3rd. The biotechnology company reported ($0.63) earnings per share for the quarter, missing analysts' consensus estimates of ($0.58) by $0.05. The biotechnology company had revenue of $1.92 million for the quarter, compared to the consensus estimate of $22.45 million. Cellectis had a negative net margin of 470.32% and a negative trailing twelve-month return on equity of 54.50%. What is André Choulika's approval rating as Cellectis' CEO? 13 employees have rated Cellectis Chief Executive Officer André Choulika on Glassdoor.com. André Choulika has an approval rating of 100% among the company's employees. This puts André Choulika in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 39.0% of employees surveyed would recommend working at Cellectis to a friend. What other stocks do shareholders of Cellectis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include Gilead Sciences (gild), Calyxt (CLXT), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Intel (INTC) and Sorrento Therapeutics (SRNE). When did Cellectis IPO? (CLLS) raised $129 million in an initial public offering (IPO) on Wednesday, March 25th 2015. The company issued 3,500,000 shares at a price of $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager. What is Cellectis' stock symbol? Cellectis trades on the NASDAQ under the ticker symbol "CLLS." Who are Cellectis' major shareholders? Cellectis' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (1.32%). How do I buy shares of Cellectis? Shares of CLLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Cellectis' stock price today? One share of CLLS stock can currently be purchased for approximately $3.10. How much money does Cellectis make? Cellectis (NASDAQ:CLLS) has a market capitalization of $141.29 million and generates $67.07 million in revenue each year. The biotechnology company earns $-114,200,000.00 in net income (profit) each year or ($2.30) on an earnings per share basis. How many employees does Cellectis have? The company employs 294 workers across the globe. How can I contact Cellectis? Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The official website for the company is www.cellectis.com. The biotechnology company can be reached via phone at (318) 169-1600, via email at investors@cellectis.com, or via fax at 33-1-81-69-16-06. This page (NASDAQ:CLLS) was last updated on 1/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.